The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist on cerebral blood flow velocity and cortical oxygination in humans without cerebrovascular disease. This study serves as a control for a similar study investigating the effect in stroke patients (ref. to EGRABIS1).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Christina Kruuse
• Treatments: Exenatide; Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Person ≥ 50 years of age

• Has given written informed consent

Exclusion Criteria:

• Intracerebral haemorrhage

• Subdural / epidural hemorrhage

• subarachnoid haemorrhage

• previously major structural damage to the brain (eg. sequelae after large stroke or brain surgery)

• Diabetes type 1

• Diabetes type 2

• Known atrial fibrillation

• > 50% stenosis of internal carotid

• Known allergy to GLP-1 receptor agonists

• Hepatic impairment (ALT> 3 x upper normal limit)

• Renal impairment (eGFR <30 ml / min)

• Inflammatory bowel disease

• Previous pancreatitis

• Heart failure (NYHA class 3-4)

• Pregnancy or lactation

• Patient not expected to co-operate to the investigations

• Visualization of the middle cerebral artery bilaterally by transcranial doppler not possible